A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.

Marcellin, P.Lau, G.Bonino, F.Farci, P.Hadziyannis, S.Jin, R.Lu, Z.Piratvisuth, T.Germanidis, G.Yurdaydın, C.Diago, M.Lai, M.Button, P.Pluck, N.2022-08-242022-08-242003-10Marcellin, P. vd. (2003). “A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B”. Hepatology, 38(4), Supplement 1, 724A-725A.0270-9139http://hdl.handle.net/11452/28349Bu çalışma, 24-28 Ekim 2003 tarihleri arasında Boston, Massachusetts[Amerika Birleşik Devletleri]’nde düzenlenen 5. Annual Meeting of the Federation’da bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/closedAccessGastroenterology & hepatologyA phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2a (40KD) (PEGASYS (R)) alone or in combination with lamivudine vs lamivudine in 546 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B.Meeting Abstract000185816701180724A725A384, Supplement 1Gastroenterology and hepatology